Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077166 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
NCT02077166 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 138 participants.
The verdict
NCT02077166, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.
Interventions
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2014-03-13 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02077166
The ClinicalTrials.gov registry entry for NCT02077166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT02077166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02077166 about?
NCT02077166 is a clinical study titled "Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.
What is the current status of trial NCT02077166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2014-03-13. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT02077166?
The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02077166?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.